FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ribociclib|DRUG: Aromatase Inhibitors, non steroideal|DRUG: LHRH agonist
Sponsor: Fondazione Sandro Pitigliani
Collaborators: Novartis